Literature DB >> 27284460

TNFRSF10C copy number variation is associated with metastatic colorectal cancer.

Daniel G Tanenbaum1, William A Hall1, Lauren E Colbert1, Amanda J Bastien1, Daniel J Brat1, Jun Kong1, Sungjin Kim1, Bhakti Dwivedi1, Jeanne Kowalski1, Jerome C Landry1, David S Yu1.   

Abstract

BACKGROUND: Genetic markers for distant metastatic disease in patients with colorectal cancer (CRC) are not well defined. Identification of genetic alterations associated with metastatic CRC could help to guide systemic and local treatment strategies. We evaluated the association of tumor necrosis factor receptor superfamily member 10C (TNFRSF10C) copy number variation (CNV) with distant metastatic disease in patients with CRC using The Cancer Genome Atlas (TCGA).
METHODS: Genetic sequencing data and clinical characteristics were obtained from TCGA for all available patients with CRC. There were 515 CRC patient samples with CNV and clinical outcome data, including a subset of 144 rectal adenocarcinoma patient samples. Using the TCGA CRC dataset, CNV of TNFRSF10C was evaluated for association with distant metastatic disease (M1 vs. M0). Multivariate logistic regression analysis with odds ratio (OR) using a 95% confidence interval (CI) was performed adjusting for age, T stage, N stage, adjuvant chemotherapy, gender, microsatellite instability (MSI), location, and surgical margin status.
RESULTS: TNFRSF10C CNV in patients with CRC was associated with distant metastatic disease [OR 4.81 (95% CI, 2.13-10.85) P<0.001] and positive lymph nodes [OR 18.83 (95% CI, 8.42-42.09)]; P<0.001) but not MSI (OR P=0.799). On multivariate analysis, after adjusting for pathologic T stage, N stage, adjuvant chemotherapy, gender, and MSI, TNFRSF10C CNV remained significantly associated with distant metastatic disease (OR P=0.018). Subset analysis revealed that TNFRSF10C CNV was also significantly associated with distant metastatic disease in patients with rectal adenocarcinoma (OR P=0.016).
CONCLUSIONS: TNFRSF10C CNV in patients with CRC is associated with distant metastatic disease. With further validation, such genetic profiles could be used clinically to support optimal systemic treatment strategies versus more aggressive local therapies in patients with CRC, including radiation therapy for rectal adenocarcinoma.

Entities:  

Keywords:  Biomarker; colorectal cancer (CRC); copy number aberration; copy number variation (CNV); genetic marker; rectal cancer

Year:  2016        PMID: 27284460      PMCID: PMC4880759          DOI: 10.21037/jgo.2015.11.04

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  38 in total

1.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

2.  Analysis on the correlation between number of lymph nodes examined and prognosis in patients with stage II colorectal cancer.

Authors:  Zhang Xingmao; Wang Hongying; Zhou Zhixiang; Wang Zheng
Journal:  Med Oncol       Date:  2013-01-08       Impact factor: 3.064

Review 3.  TRAIL signalling: decisions between life and death.

Authors:  Christina Falschlehner; Christoph H Emmerich; Björn Gerlach; Henning Walczak
Journal:  Int J Biochem Cell Biol       Date:  2007-02-14       Impact factor: 5.085

4.  A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Authors:  Zev A Wainberg; Wells A Messersmith; Parvin F Peddi; Amy V Kapp; Avi Ashkenazi; Stephanie Royer-Joo; Chia C Portera; Mark F Kozloff
Journal:  Clin Colorectal Cancer       Date:  2013-09-27       Impact factor: 4.481

5.  MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children.

Authors:  G P Tonini; L Boni; A Pession; D Rogers; A Iolascon; G Basso; L Cordero di Montezemolo; F Casale; A Pession; P Perri; K Mazzocco; P Scaruffi; C Lo Cunsolo; N Marchese; C Milanaccio; M Conte; P Bruzzi; B De Bernardi
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

Review 6.  Death receptor agonists as a targeted therapy for cancer.

Authors:  Jeffrey Wiezorek; Pamela Holland; Jonathan Graves
Journal:  Clin Cancer Res       Date:  2010-03-02       Impact factor: 12.531

Review 7.  Genetic predisposition to colorectal cancer.

Authors:  Albert de la Chapelle
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

8.  Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.

Authors:  Caroline M van Geelen; Jantine L Westra; Elisabeth G de Vries; Wytske Boersma-van Ek; Nynke Zwart; Harry Hollema; H Marike Boezen; Nanno H Mulder; John T Plukker; Steven de Jong; Jan H Kleibeuker; Jan J Koornstra
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

9.  Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.

Authors:  Tom M Ganten; Jaromir Sykora; Ronald Koschny; Emanuela Batke; Sebastian Aulmann; Ulrich Mansmann; Wolfgang Stremmel; Hans-Peter Sinn; Henning Walczak
Journal:  J Mol Med (Berl)       Date:  2009-08-13       Impact factor: 4.599

10.  Identification of a characteristic copy number alteration profile by high-resolution single nucleotide polymorphism arrays associated with metastatic sporadic colorectal cancer.

Authors:  María González-González; Celia Fontanillo; María M Abad; María L Gutiérrez; Ines Mota; Oscar Bengoechea; Ángel Santos-Briz; Oscar Blanco; Emilio Fonseca; Juana Ciudad; Manuel Fuentes; Javier De Las Rivas; José A Alcazar; Jacinto García; Luís Muñoz-Bellvis; Alberto Orfao; José M Sayagués
Journal:  Cancer       Date:  2014-03-25       Impact factor: 6.860

View more
  7 in total

Review 1.  Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer.

Authors:  Elaine S Tan; Todd C Knepper; Xuefeng Wang; Jennifer B Permuth; Liang Wang; Jason B Fleming; Hao Xie
Journal:  Cancers (Basel)       Date:  2022-04-29       Impact factor: 6.575

2.  Identification and meta-analysis of copy number variation-driven circadian clock genes for colorectal cancer.

Authors:  Wenliang Yuan; Li Liu; Cai Wei; Xiaobo Li; Dan Sun; Chaoxu Dai; Sicong Li; Sihua Peng; Linhua Jiang
Journal:  Oncol Lett       Date:  2019-09-09       Impact factor: 2.967

3.  Development of a risk scoring system for evaluating the prognosis of patients with Her2-positive breast cancer.

Authors:  Chundi Gao; Jing Zhuang; Huayao Li; Cun Liu; Chao Zhou; Lijuan Liu; Fubin Feng; Changgang Sun; Jibiao Wu
Journal:  Cancer Cell Int       Date:  2020-04-15       Impact factor: 5.722

4.  Novel Immune-Related Ferroptosis Signature in Esophageal Cancer: An Informatics Exploration of Biological Processes Related to the TMEM161B-AS1/hsa-miR-27a-3p/GCH1 Regulatory Network.

Authors:  Min Lu; Jiaqi Li; Xin Fan; Fei Xie; Jie Fan; Yuanping Xiong
Journal:  Front Genet       Date:  2022-02-24       Impact factor: 4.599

5.  Identification of immune-related ferroptosis prognostic marker and in-depth bioinformatics exploration of multi-omics mechanisms in thyroid cancer.

Authors:  Xin Fan; Fei Xie; Lingling Zhang; Chang Tong; Zhiyuan Zhang
Journal:  Front Mol Biosci       Date:  2022-08-17

6.  TNFRSF10C methylation is a new epigenetic biomarker for colorectal cancer.

Authors:  Cong Zhou; Ranran Pan; Haochang Hu; Bin Li; Jie Dai; Xiuru Ying; Hang Yu; Jie Zhong; Yiyi Mao; Yihan Zhang; Dongping Wu; Shiwei Duan
Journal:  PeerJ       Date:  2018-09-13       Impact factor: 2.984

7.  A Genome-Wide Investigation of Effects of Aberrant DNA Methylation on the Usage of Alternative Promoters in Hepatocellular Carcinoma.

Authors:  Yuting Dong; Xiaozhao Liu; Bijun Jiang; Siting Wei; Bangde Xiang; Ruichu Liao; Qiuyan Wang; Ximiao He
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.